Marimastat Synthesis Using Crystallization Instead of Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing marimastat lack detailed procedures for intermediate steps, yield data, and purity information, making it difficult to achieve high chemical and enantiomeric purity suitable for pharmaceutical use.
Innovation Solution
A process involving specific reaction conditions and solvent use to convert (2S,3R)-2-hydroxy-3-isobutylsuccinic acid to (R)-2-((S)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)-4-methylpentanoic acid, followed by reaction with (S)-2-amino-N,3,3-trimethylbutanamide, and then with hydroxylamine, eliminating chromatographic purification steps to achieve crystalline marimastat with >99% purity and 70-78% yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing synthesis methods are used, then marimastat can be prepared, but the process lacks detailed procedures and purity information making it difficult to achieve high chemical and enantiomeric purity
Solution Approach 1:
The patent specifies precise parameter ranges for reaction conditions (temperature: 35-55°C, time: 15-30 h, catalyst amount: 0.01-1 eq) to achieve high purity marimastat. By optimizing these parameters, the process achieves >99% chemical and enantiomeric purity while providing complete procedural information for reproducibility.
Solution Approach 2:
The patent replaces complex chromatographic purification systems with a simplified crystallization process. By controlling cooling rates and pH conditions during crystallization, the method achieves high purity without requiring expensive chromatographic equipment, thus providing complete procedural details without loss of information.
2Manufacturing precision
If detailed procedures and purification steps are implemented, then high purity marimastat can be obtained, but the process complexity and cost increase
Solution Approach 1:
The patent extracts and eliminates unnecessary chromatographic purification steps from the synthesis process. By focusing on optimizing the crystallization step and using selective precipitation, the method achieves high purity while significantly reducing process complexity and equipment requirements.
Solution Approach 2:
The patent employs simple, inexpensive reagents and equipment for purification (e.g., pH adjustment, filtration, crystallization) instead of expensive chromatographic systems. This approach maintains high purity while minimizing device complexity and operational costs.
3Productivity
If conventional reagents and conditions are used, then the synthesis can proceed, but hazardous conditions and high costs are incurred
Solution Approach 1:
The patent converts potentially hazardous reaction conditions into beneficial controlled processes. By using mild acid catalysts (p-TsOH, PPTS, CSA) and controlling temperature (35-55°C), the method achieves high yield while eliminating hazardous conditions associated with stronger acids and higher temperatures.
Solution Approach 2:
The patent optimizes reaction parameters (temperature, catalyst concentration, solvent choice) to achieve high yield under safe conditions. By adjusting these parameters, the process maintains productivity while avoiding hazardous reagents and conditions, using instead benign substances like water-soluble catalysts and common solvents.
4Manufacturing precision
If additional purification steps are added, then purity can be improved, but the process time and cost increase
Solution Approach 1:
The patent performs preliminary purification actions during the synthesis process itself rather than adding separate purification steps afterward. By controlling crystallization conditions and using selective precipitation during the reaction, the method achieves high purity simultaneously with product formation, eliminating time-consuming post-purification steps.
Solution Approach 2:
The patent merges the synthesis and purification operations into a single integrated process. By combining crystallization with the reaction step and using in-situ purification techniques, the method achieves high purity without requiring separate purification steps, thus reducing total process time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process yields marimastat with high chemical and enantiomeric purity, meeting pharmaceutical standards without additional purification, and is scalable for GMP production, reducing costs through the use of cheaper reagents and avoiding hazardous conditions.
Implementation Method 1
reacted in the environment of 2,2-dimethoxypropane with the addition of p-toluenesulfonic acid (p-TsOH), pyridinium p-toluenesulfonate (PPTS) or 10-camphorsulfonic acid (CSA)
Implementation Method 2
then the reaction mixture is subjected to azeotropic distillation process in order to remove water
Data Source
AI summary
The invention relates to a process for the preparation of marimastat. The invention further relates to marimastat prepared by the process, and a pharmaceutical composition comprising said marimastat. The invention also relates to the pharmaceutical composition for use as a medicament, and said marimastat for use as a medicament. The invention further relates to the pharmaceutical composition for use in the prevention and treatment of diseases associated with hyperactivity of extracellular matrix metalloproteinases, and said marimastat for use in the prevention and treatment of diseases associated with hyperactivity of extracellular matrix metalloproteinases.